Harnessing Approved and Emerging FcRn Blockers Across Subtypes in Antibody-Positive Generalized Myasthenia Gravis - CME - Guideline Central

CME

Title
Harnessing Approved and Emerging FcRn Blockers Across Subtypes in Antibody-Positive Generalized Myasthenia Gravis
Link
Description
Join us for a dynamic, case-based discussion exploring how emerging therapies are reshaping the management of generalized myasthenia gravis (gMG). As the treatment landscape rapidly evolves, clinicians must deepen their understanding of the pharmacology, efficacy, and safety of new agents to make informed, personalized treatment decisions. This program will highlight the importance of autoantibody testing, the limitations of traditional therapies, and the persistent burden of disease, and the important role of FcRn blockers in addressing current unmet needs. Two expert neurologists will share practical strategies for selecting the right therapy for the right patient—illustrated through real-world vignettes that showcase the gMG journey and the power of shared decision-making.
Target Audience
The primary target audience for this activity are neurology health care professionals (HCPs).
Learning Objectives
  • Recognize the importance of autoantibody testing to confirm a diagnosis of gMG and determine a disease subtype
  • Describe the burden of disease and limitation of traditional treatments in gMG, including the unmet need for sustained disease control and alleviating treatment-related toxicity
  • Differentiate new and emerging FcRn blockers based on pharmacodynamic characteristics, the latest clinical data on different antibody-positive subgroups, administration route and dosing, and impact on disease control
Estimated Duration
60 minutes
Delivery Mode
Online
Format
Online Learning
Specialties
Neurology
Keywords
myasthenia gravis, FcRn Blockers
Disclosures and Disclaimers
Disclosures: All relevant financial relationships for anyone with the ability to control the content of this educational activity have been mitigated. Disclaimer: Content is current as of the date this activity was released. The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred.
Accredited Providers
  • Partners for Advancing Clinical Education
  • MedliveCME
Commercial Support
  • Johnson & Johnson
  • UCB Pharma Inc
Activity Expiration Date
September 30, 2026
Credit Information
Credit TypeUnits / Unit TypeBoard
AMA PRA Category 1 Credit1 CreditsACCME- Accreditation Council for Continuing Medical Education
You rely on Guideline Central for transparency

Guideline Central and select third party use “cookies” on this website to enhance the user experience.

This technology helps us gather statistical and analytical information to optimize the relevant content for you.

The user also has the option to opt-out which may have an effect on the browsing experience.